logo
logo

Evommune Closes $50 Million Series B Financing To Advance Broad Pipeline Of Therapies To Treat Chronic Inflammatory Diseases

Apr 26, 2023•over 2 years ago

Amount Raised

$50 Million

Round Type

series b

Palo AltoBiotechnologyHealth Care

Investors

Andera PartnersPivotal Bio Venture PartnersAmplitude VenturesSym BiosisEqt Life SciencesArix Bioscience

Description

Evommune, Inc., a clinical-stage biotechnology company discovering and developing new ways to treat inflammatory diseases, today announced the completion of a $50 million Series B financing. The financing was co-led by new investor Arix Bioscience and current investors EQT Life Sciences and SymBiosis, with participation from new and existing investors including Amplitude Ventures, and Series A leads Pivotal bioVenture Partners and Andera Partners.

Company Information

Company

Evommune

Location

Palo Alto, California, United States

About

Evommune, Inc. is a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases. The company is creating game-changing science with the goal of delivering therapies that address symptoms and halt progressive disease.

Related People

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech